Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.
Cancer Research|November 6, 2009
Microenvironmental independence associated with tumor progressionAlexander R A Anderson, Mohamed Hassanein, Kevin M Branch, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLCPragya Kumar, Menkara Henry, Julia Pelesko, et al.
Research Square|May 2, 2025
Multifactorial stroma-mediated resistance is a major contributor to residual disease under targeted therapies in lung cancersBina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Nature Communications|May 29, 2026
Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapiesBina Desai, Tatiana Miti, Sandhya Prabhakaran, et al.
Neuro-Oncology|May 17, 2014
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation statusAnne L Baldock, Kevin Yagle, Donald E Born, et al.
NPJ Systems Biology and Applications|January 26, 2026
The future of mathematical oncology in the age of AIRussell C Rockne, Morten Andersen, Alexander R A Anderson, et al.
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Pageof 16